A carregar...
Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway
BACKGROUND: Palbociclib, a specific inhibitor of CDK4/6, has been shown to provide a survival benefit in hormone receptor-positive advanced breast cancer; however, its resistance and related mechanisms are unclear. MATERIAL/METHODS: In this study, we constructed palbociclib-resistant hormone recepto...
Na minha lista:
| Publicado no: | Med Sci Monit |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
International Scientific Literature, Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6327776/ https://ncbi.nlm.nih.gov/pubmed/30605443 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.912929 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|